Geneitc recombinant human albumin injection from Hepalink Biotech was approved domestically.

On July 18th, the official website of the National Medical Products Administration showed that the Administration approved the application of Wuhan Heye Biotechnology Co., Ltd. to market recombinant human albumin injection through the priority review and approval procedure, which is used in the treatment of hypoalbuminemia in patients with liver cirrhosis. It is reported that this product is the first domestically approved recombinant human albumin product.